Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075271 | 0.86 | CYP3A4 (0.40) | L3MBTL1ATMALDH1A1KMT2ADPP4 | |
| SCHEMBL12727058 | 0.86 | CYP3A4 (0.40) | L3MBTL1ATMALDH1A1KMT2ADPP4 | |
| SCHEMBL10281921 | 0.86 | CYP3A4 (0.40) | L3MBTL1ATMALDH1A1KMT2ADPP4 | |
| SCHEMBL15765640 | 0.85 | DPP4 (0.36) | ALDH1A1KMT2ADPP4DPP8DPP9 | |
| SCHEMBL13014798 | 0.83 | DPP4 (0.35) | ALDH1A1DPP4DPP8DPP9ELANE | |
| SCHEMBL10299215 | 0.82 | ELANE (0.46) | ELANELMNAMAPTKDM4E | |
| SCHEMBL5993642 | 0.81 | ELANE (0.43) | ELANELMNAMAPTKDM4EXPNPEP1 | |
| SCHEMBL5993884 | 0.80 | ATM (0.38) | L3MBTL1ATMALDH1A1KMT2AELANE | |
| SCHEMBL12824411 | 0.78 | ALDH1A1 (0.35) | L3MBTL1ATMALDH1A1KMT2ADPP4 | |
| SCHEMBL20707006 | 0.77 | CYP3A4 (0.39) | L3MBTL1DPP4DPP8DPP9ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | L3MBTL1 2364/4885ATM 4146/4885ALDH1A1 2858/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | L3MBTL1 2364/4885ATM 4146/4885ALDH1A1 2858/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | L3MBTL1 2364/4885ATM 4146/4885ALDH1A1 2858/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | L3MBTL1 2364/4885ATM 4146/4885ALDH1A1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.